RPTX News and Press, Repare Therapeutics Inc. From 04/11/22

RP-3500 shows robust activity in ovarian cancer demonstrating 75% CBR, with 25% ORR and mPFS of 35 weeks Updated monotherapy results show 43% CBR in solid tumors across genotypes, and potential best-in-class safety and tolerability Encouraging data in tumors harboring ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Comprehensive Phase 1 monotherapy data from the phase 1/2 TRESR trial will be presented at AACR on Monday, April 11, 2022 at 3:05 p.m. CT Company to host conference call on Monday, April 11, 2022 at 6:30 p.m. ET Repare Therapeutics Inc. (“Repare” or the...

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced it has bee...

Repare Therapeutics (NASDAQ:RPTX) said its drug RP-3500 continues to show that it was well tolerated in a phase 1/2 TRESR trial of RP-3500 for solid tumors with certain genomic alterations. The phase 1/2 dose-escalation and expansion trial, is designed to establish the recommended phase ...

Dose optimization provides robust evidence to advance RP-3500 into Phase 2 studies with a recommended dose and schedule Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enable...

Repare Therapeutics press release (NASDAQ:RPTX): Q4 GAAP EPS of -$0.70 beats by $0.02. Revenue of $6.88M (+4814.3% Y/Y) beats by $3.6M. For further details see: Repare Therapeutics GAAP EPS of -$0.70 beats by $0.02, revenue of $6.88M beats by $3.6M

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial r...

The following slide deck was published by Repare Therapeutics Inc. in conjunction with this event. For further details see: Repare Therapeutics (RPTX) Investor Presentation - Slideshow

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that membe...